Drug intelligence / Profile preview

Anflu

Development stage: Approved
Lead developer: Sinovac Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Anflu** is Sinovac's preservative-free, unadjuvanted seasonal **trivalent inactivated split-virion influenza vaccine**. It is produced from WHO-recommended influenza strains propagated in embryonated chicken eggs, then harvested, inactivated, purified, and disrupted. The product is designed to induce strain-specific humoral immunity against the included influenza A/H1N1, influenza A/H3N2, and influenza B vaccine strains for prevention of seasonal influenza. Anflu was introduced into clinical trials in 2003, launched in China in 2006, and its approved population includes individuals aged 6 months and older. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4181027/))

Brand names: Anflu
Other names: Influenza Vaccine Split Virion Inactivated Trivalent

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Anflu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anflu.

Explore the full profile